Incremental Cost-Utility Ratio of Intravitreal Aflibercept Compared with Ranibizumab for the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion

被引：0

作者：

Cruess, Alan F. ^{[1
]}

Jeddi, Mark ^{[2
]}

Goeree, Ron ^{[3
]}

Blackhouse, Gord ^{[3
]}

Eriksson, Marianne ^{[2
]}

机构：

[1] Dalhousie Univ, Ophthalmol, Halifax, NS, Canada

[2] Bayer, Toronto, ON, Canada

[3] McMaster Univ, Fac Hlth Sci, Hamilton, ON, Canada

来源：

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2014年 / 55卷 / 13期

关键词：

749 vascular occlusion/vascular occlusive disease; 460 clinical (human) or epidemiologic studies: health care delivery/economics/manpower; 748 vascular endothelial growth factor;

D O I：

暂无

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

6089

引用

页数：3